TransMedics

Canaccord Genuity Acts as Financial Advisor to TransMedics Group, Inc. on its Acquisition of Warm Perfusion EVOSS and Cold Perfusion LifeCradle Technologies from Bridge to Life Ltd.

Canaccord Genuity is pleased to announce that on August 2, 2023, TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states, has acquired from Bridge to Life Ltd. (“Bridge to Life”), assets and intellectual property related to the Ex-Vivo Organ Support System (“EVOSS”) and LifeCradle Heart Preservation Transport System (“LifeCradle”) technologies.

Canaccord Genuity acted as financial advisor to TransMedics in connection with the transaction.

EVOSS is a warm perfusion device designed for lung transplantation and LifeCradle is a cold perfusion device designed for heart transplantation. TransMedics intends to further develop these technologies as the Company expands its product offerings and indications for organ transplantation.

TransMedics is the world’s leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. The Company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung and liver failure.

Canaccord Genuity is focused on the corporate finance needs associated with growth companies in the United States, Canada, Europe and Asia. We are structured to provide our clients with a full range of global investment banking services, including corporate finance, research, sales and trading. Our thematic research focusing on companies around the world provides our firm with unique access to growth investors. In the last twelve months, the firm advised on approximately 100 M&A assignments globally.